{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:45:59Z","timestamp":1770511559539,"version":"3.49.0"},"reference-count":61,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2014,5,23]],"date-time":"2014-05-23T00:00:00Z","timestamp":1400803200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0098099","type":"journal-article","created":{"date-parts":[[2014,5,23]],"date-time":"2014-05-23T20:26:46Z","timestamp":1400876806000},"page":"e98099","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":14,"title":["The Influence of 5-HTTLPR Genotype on the Association between the Plasma Concentration and Therapeutic Effect of Paroxetine in Patients with Major Depressive Disorder"],"prefix":"10.1371","volume":"9","author":[{"given":"Tetsu","family":"Tomita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Yasui-Furukori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taku","family":"Nakagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoko","family":"Tsuchimine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masamichi","family":"Ishioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Kaneda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunao","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,5,23]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psyneuen.2005.04.004","article-title":"Depressive disorders \u2013 is it time to endorse different pathophysiologies?","volume":"31","author":"IA Antonijevic","year":"2006","journal-title":"Psychoneuroendocrinology"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"van Praag HM (2008) Kraepelin, biological psychiatry, and beyond. Eur Arch Psychiatry Clin Neurosci (Suppl 2): 29\u201332.","DOI":"10.1007\/s00406-008-2006-1"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4088\/JCP.09m05398blu","article-title":"Identifying depressive subtypes in a large cohort study: results from the Netherlands Study of Depression and Anxiety (NESDA)","volume":"71","author":"F Lamers","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1521\/pedi.19.1.68.62177","article-title":"The impact of parental borderline personality disorder on vulnerability to depression in children of affectively ill parents","volume":"19","author":"JR Abela","year":"2005","journal-title":"J Pers Disord"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/sj.mp.4000818","article-title":"Variability in the 5-HT(2A) receptor gene is associated with seasonal pattern in major depression","volume":"6","author":"B Arias","year":"2001","journal-title":"Mol Psychiatry"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1126\/science.1083968","article-title":"Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene","volume":"301","author":"A Caspi","year":"2003","journal-title":"Science"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2165\/00003088-197702020-00001","article-title":"Serum level monitoring and clinical pharmacokinetics of lithium","volume":"2","author":"A Amdisen","year":"1977","journal-title":"Clin Pharmacokinet"},{"key":"ref8","first-page":"1048","article-title":"Drug therapy reviews: clinical pharmacology of antiepileptic drugs","volume":"35","author":"TR Browne","year":"1978","journal-title":"Am J Hosp Pharm"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00007691-198001000-00009","article-title":"Serum concentration and clinical supervision in monitoring of lithium treatment","volume":"2","author":"A Amdisen","year":"1980","journal-title":"Ther Drug Monit"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1176\/ajp.137.6.653","article-title":"The clinical application of tricyclic antidepressant pharmacokinetics and plasma levels","volume":"137","author":"J Amsterdam","year":"1980","journal-title":"Am J Psychiatry"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1176\/ajp.142.2.155","article-title":"Tricyclic antidepressants\u2013blood level measurements and clinical outcome: an APA Task Force report","volume":"142","author":"Psychiatry Task Force on the Use of Laboratory Tests in","year":"1985","journal-title":"Am J Psychiatry"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00003088-198713060-00003","article-title":"The relationship between antidepressant response and tricyclic antidepressant plasma concentrations. A retrospective analysis of the literature using logistic regression analysis","volume":"13","author":"PJ Perry","year":"1987","journal-title":"Clin Pharmacokinet"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00003088-198916010-00002","article-title":"Therapeutic drug monitoring of cyclosporin. Practical applications and limitations","volume":"16","author":"V Rodighiero","year":"1989","journal-title":"Pharmacokinet"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/00007691-199312000-00008","article-title":"Dose-response and concentration-response relationships: clinical and regulatory perspectives","volume":"15","author":"R Lieberman","year":"1993","journal-title":"Ther Drug Monit"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/00004714-199408000-00002","article-title":"Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response","volume":"14","author":"PJ Perry","year":"1994","journal-title":"J Clin Psychopharmacol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/00007691-199608000-00019","article-title":"Role of pharmacokinetic-pharmacodynamic principles in rational and cost-effective drug development","volume":"18","author":"R Lieberman","year":"1996","journal-title":"Ther Drug Monit"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00003088-199732020-00001","article-title":"Will routine therapeutic drug monitoring have a place in clozapine therapy?","volume":"32","author":"DJ Freeman","year":"1997","journal-title":"Clin Pharmacokinet"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1055\/s-2003-39983","article-title":"Therapeutic drug monitoring of tricyclic antidepressants: how does it work under clinical conditions?","volume":"36","author":"MJ M\u00fcller","year":"2003","journal-title":"Pharmacopsychiatry"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Pfuhlmann B, Gerlach M, Burger R, Gonska S, Unterecker S, <etal>et al<\/etal>.. (2007) Therapeutic drug monitoring of tricyclic antidepressants in everyday clinical practice. J Neural Transm Suppl 72: 287\u2013296.","DOI":"10.1007\/978-3-211-73574-9_35"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":"AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011","volume":"44","author":"C Hiemke","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"ref21","first-page":"18","article-title":"Clinical effects of serotonin reuptake inhibitors in the treatment of depressive illness","volume":"49","author":"GD Burrows","year":"1988","journal-title":"J Clin Psychiatry"},{"key":"ref22","first-page":"85","article-title":"Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders","volume":"55","author":"NS Gunasekara","year":"1998","journal-title":"Drugs"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Haddock RE, Johnson AM, Langley PF, Nelson DR, Pope JA, <etal>et al<\/etal>.. (1989) Metabolic pathway of paroxetine in animals and man and the comparative pharmacological properties of its metabolites. Acta Psychiatr Scand Suppl 350: 24\u201326.","DOI":"10.1111\/j.1600-0447.1989.tb07163.x"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, <etal>et al<\/etal>.. (1989) A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand Suppl 350: 60\u201375.","DOI":"10.1111\/j.1600-0447.1989.tb07176.x"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2165\/00003088-199324030-00003","article-title":"Clinical pharmacokinetics of selective serotonin reuptake inhibitors","volume":"24","author":"J van Harten","year":"1993","journal-title":"Clin Pharmacokinet"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1600-0447.1989.tb07201.x","article-title":"Paroxetine plasma levels: lack of correlation with efficacy or adverse events","volume":"Suppl350","author":"TC Tasker","year":"1989","journal-title":"Acta Psychiatr Scand"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0165-0327(90)90081-I","article-title":"Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study","volume":"18","year":"1990","journal-title":"J Affect Disord"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1055\/s-2004-818990","article-title":"Paroxetine in major depression: correlating plasma concentrations and clinical response","volume":"37","author":"C Normann","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00213-011-2319-z","article-title":"&quot;There is no dose-response relationship in psychopharmacotherapy&quot; vs &quot;pharmacotherapy in psychiatry is based on ligand-receptor interaction&quot;: a unifying hypothesis and the need for plasma concentration based clinical trials","volume":"217","author":"V Eggart","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1034\/j.1600-0447.2000.101005354.x","article-title":"Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients","volume":"101","author":"J Lundmark","year":"2000","journal-title":"Acta Psychiatr Scand"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.pnpbp.2007.02.003","article-title":"Time course of response to paroxetine: influence of plasma level","volume":"31","author":"M Gex-Fabry","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1055\/s-2005-864121","article-title":"Paroxetine serum concentrations in depressed patients and response to treatment","volume":"38","author":"M Gilles","year":"2005","journal-title":"Pharmacopsychiatry"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/hup.1252","article-title":"Inverse correlation between clinical response to paroxetine and plasma drug concentration in patients with major depressive disorders","volume":"26","author":"N Yasui-Furukori","year":"2011","journal-title":"Hum Psychopharmacol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1126\/science.274.5292.1527","article-title":"Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region","volume":"274","author":"KP Lesch","year":"1996","journal-title":"Science"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.biopsych.2004.01.029","article-title":"Serotonin transporter promoter and intron 2 polymorphisms: relationship between allelic variants and gene expression","volume":"55","author":"D Hranilovic","year":"2004","journal-title":"Biol Psychiatry"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/BF01273314","article-title":"The human serotonin transporter gene polymorphism\u2014basic research and clinical implications","volume":"104","author":"A Heils","year":"1997","journal-title":"J Neural Transm"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1192\/bjp.bp.108.062521","article-title":"Moderation of antidepressant response by the serotonin transporter gene","volume":"195","author":"P Huezo-Diaz","year":"2009","journal-title":"Br J Psychiatry"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00213-009-1550-3","article-title":"Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response","volume":"205","author":"W Min","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00406-010-0126-x","article-title":"Is 5-HTTLPR linked to the response of selective serotonin reuptake inhibitors in MDD?","volume":"261","author":"A Illi","year":"2011","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/BF01276434","article-title":"Organization of the human serotonin transporter gene","volume":"95","author":"KP Lesch","year":"1994","journal-title":"J Neural Transm Gen Sect"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1046\/j.1471-4159.1996.66062621.x","article-title":"Allelic variation of human serotonin transporter gene expression","volume":"66","author":"A Heils","year":"1996","journal-title":"J Neurochem"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1124\/mi.4.2.8","article-title":"Serotonin transporter: gene, genetic disorders, and pharmacogenetics","volume":"4","author":"DL Murphy","year":"2004","journal-title":"Mol Interv"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s00406-008-0842-7","article-title":"Association of the s allele of the 5-HTTLPR with neuroticism-related traits and temperaments in a psychiatrically healthy population","volume":"259","author":"X Gonda","year":"2009","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/sj.mp.4000425","article-title":"Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine","volume":"3","author":"E Smeraldi","year":"1998","journal-title":"Mol Psychiatry"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/sj.mp.4001926","article-title":"Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients","volume":"12","author":"A Serretti","year":"2007","journal-title":"Mol Psychiatry"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/sj.tpj.6500491","article-title":"Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy","volume":"9","author":"MJ Wilkie","year":"2009","journal-title":"Pharmacogenomics J"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1176\/ps.2009.60.11.1446","article-title":"Pharmacogenetics studies in STAR*D: strengths, limitations, and results","volume":"60","author":"G Laje","year":"2009","journal-title":"Psychiatr Serv"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"SA Montgomery","year":"1979","journal-title":"Br J Psychiatry"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/hup.576","article-title":"The inter-rater reliability of the Japanese version of the Montgomery-Asberg depression rating scale (MADRS) using a structured interview guide for MADRS (SIGMA)","volume":"19","author":"N Takahashi","year":"2004","journal-title":"Hum Psychopharmacol"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987) The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334: 1\u2013100.","DOI":"10.1111\/j.1600-0447.1987.tb10566.x"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00228-006-0217-9","article-title":"Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects","volume":"63","author":"N Yasui-Furukori","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/FTD.0b013e31802bb20d","article-title":"Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters","volume":"29","author":"N Yasui-Furukori","year":"2007","journal-title":"Ther Drug Monit"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1055\/s-0031-1291347","article-title":"The serotonin transporter promoter polymorphism (5-HTTLPR) affects the relation between antidepressant serum concentrations and effectiveness in major depression","volume":"45","author":"N Dreim\u00fcller","year":"2012","journal-title":"Pharmacopsychiatry"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1523\/JNEUROSCI.3769-04.2005","article-title":"A functional genetic variation of the serotonin (5-HT) transporter affects 5-HT1A receptor binding in humans","volume":"25","author":"SP David","year":"2005","journal-title":"J Neurosci"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1177\/0269881109106899","article-title":"Predictive factors for responding to sertraline treatment: views from plasma catecholamine metabolites and serotonin transporter polymorphism","volume":"24","author":"W Umene-Nakano","year":"2010","journal-title":"J Psychopharmacol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000341876","article-title":"Association between serotonin transporter-linked polymorphic region and escitalopram antidepressant treatment response in Korean patients with major depressive disorder","volume":"66","author":"ES Won","year":"2012","journal-title":"Neuropsychobiology"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/sj.mp.4000334","article-title":"Serotonin transporter gene polymorphisms: ethnic difference and possible association with bipolar affective disorder","volume":"2","author":"H Kunugi","year":"1997","journal-title":"Mol Psychiatry"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.euroneuro.2009.01.010","article-title":"Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression","volume":"19","author":"E Maron","year":"2009","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000317285","article-title":"Norepinephrine and serotonin transporter genes: impact on treatment response in depression","volume":"62","author":"A Baffa","year":"2010","journal-title":"Neuropsychobiology"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.pnpbp.2010.04.020","article-title":"Serotonin transporter gene polymorphisms and treatment-resistant depression","volume":"34","author":"C Bonvicini","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.pnpbp.2013.05.011","article-title":"Pharmacogenetics in major depression: A comprehensive meta-analysis","volume":"45","author":"T Niitsu","year":"2013","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0098099","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T22:46:16Z","timestamp":1565477176000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0098099"}},"subtitle":[],"editor":[{"given":"Kent E.","family":"Vrana","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,5,23]]},"references-count":61,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,5,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0098099","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,23]]}}}